We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

The Effect of Dexmedetomidine on Postoperative Analgesia

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: June 14, 2011
Last Update Posted: March 8, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Pharmbio Korea Co., Ltd.
Information provided by (Responsible Party):
Yong Chul Kim, Seoul National University Hospital
The purpose of this study is to determine whether additional Dexmedetomidine to patient controlled analgesia can reduce fentanyl consumption.

Condition Intervention Phase
Colon Cancer, Rectal Cancer Drug: Fentanyl Drug: Dexmedetomidine Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: Assessment of the Effect of Dexmedetomidine in the Management of Postoperative Pain When Combined With Fentanyl in the Patient-controlled Analgesia

Resource links provided by NLM:

Further study details as provided by Yong Chul Kim, Seoul National University Hospital:

Primary Outcome Measures:
  • total amount of administered fentanyl [ Time Frame: during first 24 hours after surgery ]

Enrollment: 95
Study Start Date: June 2011
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: F
Fentanyl+Normal saline
Drug: Fentanyl
Fentanyl 2500mcg+NS50ml
Experimental: D
Drug: Dexmedetomidine
Fentanyl 2500mcg+Dexmedetomidine 500mcg + NS 45ml


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Elective surgery for colon cancer

Exclusion Criteria:

  • Liver disease
  • Kidney disease
  • Allergy for study drugs
  • Inability to receive patient controlled analgesia
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01373021

Korea, Republic of
Seoul national university hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
Pharmbio Korea Co., Ltd.
  More Information

Responsible Party: Yong Chul Kim, Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT01373021     History of Changes
Other Study ID Numbers: sunrud1129
First Submitted: June 13, 2011
First Posted: June 14, 2011
Last Update Posted: March 8, 2012
Last Verified: March 2012

Additional relevant MeSH terms:
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Analgesics, Opioid
Adjuvants, Anesthesia
Anesthetics, Intravenous